Amgen Reports In-Line Q4 EPS, Offers FY23 Guidance
Amgen (AMGN) reported Q4 EPS of $4.09, in-line with the analyst estimate of $4.09. Revenue for the quarter came in at $6.8 billion versus the consensus estimate of $6.74...
Neutral
or
Amgen News & Analysis
-
-
Amgen earnings matched, revenue topped estimates
Investing.com - Amgen (NASDAQ: AMGN) reported fourth quarter EPS of $4.09, in line with the analyst estimate of $4.09. Revenue for the quarter came in at $6.8B versus the consensus estimate...
-
Amgen launches an AbbVie Humira biosimilar in the U.S.
By Sam Boughedda After a dip earlier in the session, AbbVie (NYSE:ABBV) shares are now slightly up on the day, holding steady, despite Amgen (NASDAQ:AMGN) announcing AMJEVITA, a biosimilar...
-
Fed meeting, Exxon record, Eurozone skirts recession - what's moving markets
By Geoffrey Smith Investing.com -- The Federal Reserve starts a two-day policy meeting against a backdrop of weakening economic data - although the International Monetary Fund has raised its...
-
: Amgen stock price target cut to $260 from $271 at UBS
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about...
-
Amgen lays off 300 employees
(Reuters) – Amgen Inc said on Monday that it had let go about 300 employees based in the United States, mainly in its commercial team, citing recent organizational changes to better...
-
Warren tells FTC she is “particularly concerned” about Amgen and Indivior deals
WASHINGTON (Reuters) – Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending...
-
5 biggest deals of 2022: Musk's Twitter buyout, Microsoft-Activision
As we head into 2023, here's a look back at a year that saw dealmaking slow into year-end amid rising interest rates by central banks, with three of the top five deals fraught with...
-
Dow, Nasdaq, and S&P 500 2022 winners and losers: energy, tech lead the way
By Daniel Shvartsman Investing.com -- Entering the last trading day of the year, it's no surprise to find the 2022 scoreboard filled with energy winners and tech losers.The Dow Jones...
-
In case you missed it, 10 big dividend hikes: Carrier Global raises by 23%
Here are the biggest fresh dividend hikes and special dividends, as first covered on InvestingPro+, including several predicted by data from InvestingPro+ and StreetInsider this month. Get a...
-
GILD vs. AMGN: Two Splendid Dividend Stocks, but One Looks Better
Investors have had a love/hate relationship with biotech stocks for years, and it’s easy to see why. Between drug trial results and patent expirati...
-
Thursday’s Top Analyst Upgrades and Downgrades: Amgen, ADM, Blackstone, Bloom Energy, Carnival, Chevron, Nike, QuantumScape, RingCentral and More
Thursday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Blackstone, Bloom Energy, Carnival, Chevron, Danaher, EQT, KKR, Nike, PACCAR, Plug Power, PulteGroup,...
-
American Kidney Fund Thanks Amgen for its Champion Level 2022 Corporate Membership
ROCKVILLE, Md., Dec. 13, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today expressed its appreciation for Amgen's participation in the 2022 class of its Corporate Membership...
-
Another Competitor For Amgen As FDA Approves Mirati Therapeutics' KRAS Inhibitor For Lung Cancer Setting
The FDA granted accelerated approval to Mirati Therapeutics Inc (NASDAQ: MRTX) Krazati (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or...
-
Midday movers: Horizon Therapeutics, Coupa Software, Microsoft and more
By Liz Moyer Investing.com -- Stocks are rising as investors await key inflation data and the Federal Reserve's decision on the next direction for interest rates. Here are the midday movers...
-
U.S. stocks rise as investors await inflation data and the Fed's rate decision
By Liz Moyer Investing.com -- Blue-chip stocks were rising but tech stocks wobbled as investors await inflation data and the Federal Reserve's next decision on interest rates later this...
-
Horizon Therapeutics, Microsoft, Gap rise premarket; Amgen, Rivian fall
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, December 12th. Please refresh for updates. Amgen (NASDAQ:AMGN) stock fell 3.2% after the Wall Street Journal...
-
Amgen secures $28.3 billion deal to buy Horizon Therapeutics
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
-
Coupa stock soars on buyout news: 5 head-turning deal reports
Here are the 5 biggest deal dispatches from this past week, as covered first on InvestingPro+. Coupa Software (NASDAQ:COUP) was recently surging 26% in premarket trade Monday on news it had...
-
Dow futures rise 45 pts; rebounding ahead of Fed, CPI data
By Peter Nurse Investing.com -- U.S. stocks are seen opening marginally higher Monday, starting an important week that includes consumer inflation data and the final Federal Reserve...
-
Amgen to acquire Horizon for $26 billion as Sanofi drops bid - report
By Senad Karaahmetovic Amgen (NASDAQ:AMGN) has agreed to acquire Horizon Therapeutics (NASDAQ:HZNP), according to Bloomberg News. Amgen agreed to pay $116.5 for each HZNP share, valuing the...
-
Sanofi shares rise after French drugmaker ditches Horizon deal talks
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) rose on Monday after the French drugmaker backed out of its plans to bid for biotech company Horizon Therapeutics PLC...
-
European stocks weaken; caution ahead of central bank meetings
By Peter Nurse Investing.com - European stock markets retreated Monday, with investors cautious ahead of policy-setting meetings from the likes of the Federal Reserve and the European...
-
Amgen set to buy biotech firm Horizon at $26 billion valuation – Bloomberg News
(Reuters) – Amgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on...
-
The Wall Street Journal: Amgen reportedly in talks to buy Horizon Therapeutics
The U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
-
Sanofi Says it does not intend to make an offer for horizon, leaving Amgen as sole bidder
(Reuters) -French health group Sanofi said on Sunday that it no longer intends to make an offer for biotech company Horizon Therapeutics Plc , leaving Amgen Inc as the only remaining...
-
Amgen Nears Deal to Buy Horizon Therapeutics
The U.S. biotech company was the last of three suitors standing in an auction for Horizon. A deal would likely be valued at well over $20 billion and mark the largest healthcare merger of...
-
Rumors buzzing around Wall Street today
By Investing.com Staff Stocks were heavy Monday as positive economic data stirred concerns the Fed will have to maintain its hawkishness on rates. Amid the downside, several rumors swirled...
-
Horizon Therapeutics downticks as one of three bidders drops out
By Investing.com Staff Horizon Therapeutics (NASDAQ:HZNP) fell nearly 5% in early trading Monday after it was disclosed that one of the three original bidders for the company dropped...
-
7 biggest deal reports this week: Horizon Therapeutics surges on takeover talks
Here are 7 head-turning deal dispatches from the past week, as covered first on InvestingPro+. 1. Arco Platform (NASDAQ:ARCE) announced it had received a non-binding going private...
-
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about...
-
Midday movers: DoorDash, Workday, Hormel and more
By Liz Moyer Investing.com -- Stocks were struggling for direction on Wednesday as investors waited to hear what Federal Reserve Chair Jerome Powell will say in a speech he is scheduled to...
-
3 rumors pushing around stocks today
By Investing.com Staff Stocks edged lower Tuesday as traders watch developments in China around protests over the county's 'zero COVID' policy. Amid the downside action, several rumors...
-
Horizon Therapeutics jumps after confirming takeover talks with 3 parties
By Investing.com Staff Shares of Horizon Therapeutics (NASDAQ:HZNP) surged over 30% after-hours Tuesday after the company confirmed that it was "highly preliminary" takeover talks with Amgen...
-
Credit Suisse initiates coverage of large-cap pharma stocks - Merck started at outperform
By Sam Boughedda Credit Suisse analysts said Friday that the firm is initiating coverage of U.S. large-cap pharmaceuticals with four Outperform ratings, two Neutral ratings, and one...
-
Wall St rises as midterm election begins; Amgen hits record high
By Amruta Khandekar and Devik Jain (Reuters) - U.S. stock indexes rose for the third straight session on Tuesday as voting began in the crucial midterm election that will determine control...
-
Amgen Beats on Revenue and Profit Expectations
By Liz Moyer Investing.com -- Amgen (AMGN) reported third quarter earnings that beat analysts' forecasts and revenue that topped expectations. The biotech company reported earnings per...
-
Amgen Beats on Revenue and Profit Expectations
By Liz Moyer Investing.com -- Amgen (NASDAQ:AMGN) reported third quarter {{erl-6466||earnings that beat analysts' forecasts and revenue that topped expectations. The biotech company...
-
Amgen Earnings, Revenue beat In Q3
Investing.com - Amgen (NASDAQ:AMGN) reported on Thursday third quarter {{erl-6466||earnings that beat analysts' forecasts and revenue that topped expectations. Amgen announced earnings per...
-
Amgen Tops Q3 EPS by 25c, Offers Guidance
Amgen (AMGN) reported Q3 EPS of $4.70, $0.25 better than the analyst estimate of $4.45. Revenue for the quarter came in at $6.7 billion versus the consensus estimate of $6.58...
-
Fed Drives Dollar Higher, BoE Hike, China Rally Stalls - What's Moving Markets
By Geoffrey Smith Investing.com -- The Federal Reserve's hawkish messaging drives the dollar higher and brings the rally in U.S. and global stocks to a shuddering halt. The Bank of England...
-
Barclays Downgrades Amgen to Underweight, Upgrades Gilead
By Senad Karaahmetovic Barclays analysts downgraded shares of Amgen (NASDAQ:AMGN) to Underweight from Equal Weight with a price target of $234 per share. With Amgen shares up over 20% in...
-
Today's Most Important Upgrades
By Davit Kirakosyan Amgen (NASDAQ:AMGN) shares were up 6% intra-day today after Morgan Stanley upgraded the company to Overweight from Equalweight and raised its price target to $279 from...
-
Amgen Stock Pops After Morgan Stanley Upgrade to Overweight
By Senad Karaahmetovic Morgan Stanley analysts upgraded shares of Amgen (NASDAQ:AMGN) to Overweight with a price target of $279 per share (up from $257). The analysts believe that the market...
-
The Key for Amgen is the 'Lack of a Black Box' - Mizuho
By Sam Boughedda Amgen (NASDAQ:AMGN) was reiterated at Neutral with a $208 per share price target by a Mizuho analyst on Monday, despite the stock's decline during the session following the...
-
Bristol-Myers Squibb Rallies as FDA's Approval of Sotyktu is a 'Best-case Scenario'
By Senad Karaahmetovic Shares of Bristol-Myers Squibb (NYSE:BMY) are up about 7% in premarket Monday after the U.S. FDA approved Deucravacitinib, now known as Sotyktu, for the treatment of...
-
Pre-Open Movers: Bed Bath & Beyond Sinks on Update, PayPal Gains on Upgrade
Pre-Open Stock Movers: Bed Bath & Beyond Inc . (NASDAQ:BBBY) 24% LOWER; provides a strategic update, announcing job cuts, store closures, a 12 million share ATM offering, loan deal, and...
-
After-Hours Movers: Chargepoint Gains Following Results, Chewy Falls
After-Hours Stock Movers:Chewy (NYSE:CHWY) 8% LOWER; reported Q2 net income of $22.3 million. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.45...
-
Amgen Reports Q2 Beat, Provides Guidance
By Investing.com Staff Amgen (NASDAQ:AMGN) reported its {{erl-6466||Q2 results, with EPS of $4.65 coming in better than the consensus estimate of $4.39. Revenue grew 1% year-over-year to...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
